cell-therapy-public-health-congress-2019-keynote

7 / 14

Note:
Page 18
April 15-16, 2019 | Milan, Italy
&
PUBLIC HEALTH,
EPIDEMIOLOGY AND NUTRITION
2nd World Congress on
CELL AND GENE THERAPY
2nd International Conference on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Joint Event on
Cell and Gene Therapy 2019 & Public Health Congress 2019 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
CELL AND GENE THERAPY: NOW IS THE
BEST TIME TO INVEST
I n the recent years author have seen the re-born of cell and gene ther-
apy approaches; the field has made very important steps toward a
concrete clinical application and this has translated in a gained interest
from investors and big corporate. 2017 FDA approval of YESCARTA, the
CART technology form Kite Pharma, is only one of the successful stories,
accounting 72% of positive responders after one single administration.
This also translated in $11.9B acquisition from Gilead. Unfortunately, the
successful clinical translation of cell and gene therapy is linked to a num-
ber of challenges they just now started to see (i.e. clinical validation, scal-
ability and pricing); to face these challenges they need great science to
meet the mind-full entrepreneurs. This is exactly what they do as venture
capitalists: they help to create value from ideas. They support the team
towards the important milestones of their product’s validation and they
guide them to the market. They do not provide financial support only
but also they provide a team of experts and KOLs that can support the
company in the identification of the best and shortest strategy to reach
the patients.
Claudio Giuliano, Arch Gen Intern Med 2019, Volume 3
DOI: 10.4066/2591-7951-C2-025
Claudio Giuliano is a player in the venture capital
industry since the year 2000. He is the co-found-
er of Innogest Capital, a venture capital firm with
about €200 mln under management and is a
partner in the Healthcare and Cardiovascular
practice at Innogest in 2007. He served as Chair-
man of the VC committee at the Italian VC and
PE Association (AIFI) and is part of several private
and public bodies involved in start-up and entre-
preneurship development. Prior to Innogest, he
was an Associate Director at The Carlyle Group,
London; Strategy consultant at Bain & Co, Italy
and Supply chain manager at Hewlett-Packard
California and France. He holds a Summa cum
Laude Master of Science in Electronic Engineer-
ing from Politecnico di Torino, Italy, a Summa
cum Laude Diplôme d’études approfondies in
Microelectronics from l’Institute Nationale Poly-
tecnique in Grenoble, France and an MBA from
INSEAD (Dean’s List), in Fontainebleau, France.
Claudio Giuliano
Innogest, Italy
BIOGRAPHY